For instance, the use of intravitreal bevacizumab injections induces a risk of neurodevelopmental delay in ROP infants, suggesting that anti-VEGF therapies may introduce a risk of developmental impairments [79]. The gene discussed is VEGFA; the disease is retinopathy of prematurity.